Literature DB >> 16873176

Gender Differences in HIV-Related Neurological Progression in a Cohort of Injecting Drug Users Followed for 3.5 Years.

X Liu1, K Marder, Y Stern, G Dooneief, K Bell, G Todak, M Joseph, W Elsadr, J B Williams, A Ehrhardt, Z Stein, R Mayeux.   

Abstract

We evaluated potential gender differences in the development of HIV related neurologic impairment, by matching 38 pairs of HIV positive male and female injecting drug users on their baseline age, education, disease stage and CD4 counts, and following them for 3.5 years. Adjusting for age, education, drug use, history of head injury and baseline CD4 count, more women had sensory abnormalities and symptoms than men at baseline, but the odds of having neurological impairment, particularly extrapyramidal signs and sensory abnormalities were increased over time in men but not in women. Men with ARC or AIDS had more neurological impairment than women in similar stages of illness. This study suggests further investigations of gender differences in HIV disease progression.

Entities:  

Mesh:

Year:  1996        PMID: 16873176     DOI: 10.1300/j128v01n04_03

Source DB:  PubMed          Journal:  J NeuroAIDS        ISSN: 1069-7438


  3 in total

1.  Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder.

Authors:  Nishiena S Gandhi; Richard T Moxley; Jason Creighton; Heidi Vornbrock Roosa; Richard L Skolasky; Ola A Selnes; Justin McArthur; Ned Sacktor
Journal:  HIV Ther       Date:  2010-05

2.  Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior.

Authors:  Yun Kyung Hahn; Elizabeth M Podhaizer; Sean P Farris; Michael F Miles; Kurt F Hauser; Pamela E Knapp
Journal:  Brain Struct Funct       Date:  2013-12-19       Impact factor: 3.270

3.  Inhibitory Control Deficits Associated with Upregulation of CB1R in the HIV-1 Tat Transgenic Mouse Model of Hand.

Authors:  Ian R Jacobs; Changqing Xu; Douglas J Hermes; Alexis F League; Callie Xu; Bhupendra Nath; Wei Jiang; Micah J Niphakis; Benjamin F Cravatt; Ken Mackie; Somnath Mukhopadhyay; Aron H Lichtman; Bogna M Ignatowska-Jankowska; Sylvia Fitting
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-01       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.